Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma Journal Article

  


Authors: Yoon, S. S.; Segal, N. H.; Olshen, A. B.; Brennan, M. F.; Singer, S.
Article Title: Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma
Abstract: Background: Tumor angiogenesis, or new blood vessel formation, is regulated by a balance between pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and anti-angiogenic factors such as endostatin. Patients and methods: To investigate this angiogenic balance in soft tissue sarcomas (STS), blood samples were collected from 76 STS patients and 15 healthy controls, and analyzed for VEGF, bFGF and endostatin using quantitative enzyme-linked immunosorbent assays (ELISA). Results: Forty-one patients (54%) had primary tumors, 20 (26%) had local recurrences and 15 (20%) had metastatic disease with or without local disease. Levels of all three angiogenic factors were highly variable in STS patients. Mean levels of VEGF and bFGF were 12 and 14 times higher, respectively, in patients compared with controls (P<0.0001). VEGF levels correlated with size of tumor, with the highest levels found in tumors > 10cm in size. Patients with metastases had endostatin levels 45% lower than patients without metastases (P=0.047). In 54 patients who underwent resection of primary disease or local recurrence, low pre-operative bFGF level was associated with a higher risk of subsequent recurrence (P = 0.044). Conclusions: STS secrete widely variable levels of angiogenic factors, and levels of specific factors may correlate with extent of disease, predict risk of recurrence and possibly guide the use of anti-angiogenic agents. © 2004 European Society for Medical Oncology.
Keywords: vasculotropin; adult; human tissue; aged; middle aged; vascular endothelial growth factor a; cancer surgery; major clinical study; case-control studies; cancer recurrence; cancer patient; recurrence risk; preoperative evaluation; metastasis; neoplasm recurrence, local; risk factors; angiogenesis; neovascularization, pathologic; enzyme linked immunosorbent assay; prediction; risk assessment; sarcoma; fibroblast growth factor 2; disease severity; statistical analysis; blood sampling; quantitative analysis; cancer size; vascular endothelial growth factor; neoplasm metastasis; soft tissue sarcoma; enzyme-linked immunosorbent assay; tumor vascularization; soft tissue neoplasms; drug use; angiogenic factor; basic fibroblast growth factor; endostatin; humans; prognosis; human; male; female; priority journal; article; endostatins
Journal Title: Annals of Oncology
Volume: 15
Issue: 8
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2004-08-01
Start Page: 1261
End Page: 1266
Language: English
DOI: 10.1093/annonc/mdh309
PROVIDER: scopus
PUBMED: 15277268
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-4444286921&partnerID=40&md5=0238cca595c626f03bd794691662f8d1
Notes: Ann. Oncol. -- Cited By (since 1996):44 -- Export Date: 16 June 2014 -- CODEN: ANONE -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Sam Yoon
    108 Yoon
  2. Murray F Brennan
    1059 Brennan
  3. Neil Howard Segal
    210 Segal
  4. Adam B Olshen
    107 Olshen
  5. Samuel Singer
    337 Singer
Related MSK Work